US President Trump signs executive order to accelerate psychedelic drug research

US President Donald Trump signed an executive order on April 19, 2026, aimed at easing restrictions on federal research into psychedelic drugs such as psilocybin and LSD.

The order is intended to reduce bureaucratic hurdles and facilitate faster studies by federal agencies.

It directs improved data sharing between the Food and Drug Administration (FDA) and the Department of Veterans Affairs and aims to expedite the rescheduling process for psychedelic drugs if they receive FDA approval.

Currently, these substances are classified as having high abuse potential, limiting their medical research and use.

The order does not immediately change the legal status of these drugs or expand their therapeutic use but focuses on accelerating research efforts.

This move comes amid growing interest in the potential mental health benefits of psychedelics, particularly for treating conditions such as anxiety and depression in war veterans.

In 2023, the Department of Veterans Affairs reported 6,398 veteran suicides, underscoring the need for alternative treatments.

During the signing ceremony at the White House, President Trump cited ibogaine, a psychedelic drug, noting claims that patients experienced an 80 to 90 percent reduction in depression and anxiety symptoms within one month.

The full extent of benefits and risks remains unclear due to previous research restrictions.

#psychedelicdrugs #executiveorder #DonaldTrump #FDA #DepartmentofVeteransAffairs #mentalhealthresearch